Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat with Continued AI in ER+ Breast Cancer
NCT00828854Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Oct 2008
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of entinostat in estrogen receptor-positive breast cancer (ER+), sponsored by Syndax Pharmaceuticals. Started Oct 2008; status: completed.
02
Drugs
entinostat
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT00828854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00828854.